We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent (A), Visiopharm Unite for Supply of Pathology Solutions
Read MoreHide Full Article
Agilent Technologies (A - Free Report) and Visiopharm have strengthened their partnership by signing an agreement for global distribution of their pathology solutions.
Agilent will offer pathologists its portfolio of automated pathology staining solutions and Visiopharm’s portfolio of CE-IVD marked AI-driven precision pathology software.
The agreement marked Europe as their first target for providing both the solutions.
Thus, the recent move is likely to expand Agilent’s reach to pathologists, which might contribute to its revenues in the near term.
Apart from the recent agreement, the company previously partnered with Visiopharm for HERE2 APP to include Agilent’s HercepTest mAb pharmDx.
Further, the agreement has helped the company in penetrating the booming digital pathology market.
The digital pathology market is witnessing a significant rise globally due to growing adoption of AI-based pathology solutions.
As these solutions offer diagnostic decision support and enhance productivity, pathologists are using these for improving diagnostic accuracy as well as workload management.
The coronavirus pandemic has further proliferated the use of these digital pathology solutions.
Per a report by Grand View Research, the market was valued at $882.7 million in 2020, and is expected to progress at a CAGR of 6.8% between 2021 and 2028.
In addition, a report by ReportLinker indicates that this market in terms of revenues is likely to grow at a CAGR of 10% from 2020 to 2026.
Thus, Agilent — with the latest move — remains well positioned to capitalize on the abovementioned prospects.
Portfolio Strength: Key Catalyst
The latest move bodes well with Agilent’s growing initiatives to bolster its portfolio and provide innovative technological solutions in life sciences, diagnostics, and applied chemical markets.
This apart, Agilent’s recent launch of three InfinityLab Bio Liquid Chromatography systems for addressing the needs of the biopharma industry is worth mentioning.
In addition, the company introduced the Agilent 8697 Headspace Sampler with integrated gas chromatography communication in the pharmaceutical space. This remains a tailwind.
It also introduced a new exome design named SureSelect Human All Exon V8 for providing extensive and latest coverage of protein coding regions from RefSeq, CCDS as well as GENCODE in both clinical and translational research.
Further, the company launched the Agilent Seahorse XF HS Miniplate for the Agilent Seahorse XF HS Mini Analyzer to help immunology and disease researchers improve immune cell metabolic analysis.
Image: Shutterstock
Agilent (A), Visiopharm Unite for Supply of Pathology Solutions
Agilent Technologies (A - Free Report) and Visiopharm have strengthened their partnership by signing an agreement for global distribution of their pathology solutions.
Agilent will offer pathologists its portfolio of automated pathology staining solutions and Visiopharm’s portfolio of CE-IVD marked AI-driven precision pathology software.
The agreement marked Europe as their first target for providing both the solutions.
Thus, the recent move is likely to expand Agilent’s reach to pathologists, which might contribute to its revenues in the near term.
Apart from the recent agreement, the company previously partnered with Visiopharm for HERE2 APP to include Agilent’s HercepTest mAb pharmDx.
Further, the agreement has helped the company in penetrating the booming digital pathology market.
Agilent Technologies, Inc. Price and Consensus
Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote
Growing Digital Pathology Market
The digital pathology market is witnessing a significant rise globally due to growing adoption of AI-based pathology solutions.
As these solutions offer diagnostic decision support and enhance productivity, pathologists are using these for improving diagnostic accuracy as well as workload management.
The coronavirus pandemic has further proliferated the use of these digital pathology solutions.
Per a report by Grand View Research, the market was valued at $882.7 million in 2020, and is expected to progress at a CAGR of 6.8% between 2021 and 2028.
In addition, a report by ReportLinker indicates that this market in terms of revenues is likely to grow at a CAGR of 10% from 2020 to 2026.
Thus, Agilent — with the latest move — remains well positioned to capitalize on the abovementioned prospects.
Portfolio Strength: Key Catalyst
The latest move bodes well with Agilent’s growing initiatives to bolster its portfolio and provide innovative technological solutions in life sciences, diagnostics, and applied chemical markets.
This apart, Agilent’s recent launch of three InfinityLab Bio Liquid Chromatography systems for addressing the needs of the biopharma industry is worth mentioning.
In addition, the company introduced the Agilent 8697 Headspace Sampler with integrated gas chromatography communication in the pharmaceutical space. This remains a tailwind.
It also introduced a new exome design named SureSelect Human All Exon V8 for providing extensive and latest coverage of protein coding regions from RefSeq, CCDS as well as GENCODE in both clinical and translational research.
Further, the company launched the Agilent Seahorse XF HS Miniplate for the Agilent Seahorse XF HS Mini Analyzer to help immunology and disease researchers improve immune cell metabolic analysis.
Zacks Rank & Other Stocks to Consider
Currently, Agilent carries a Zacks Rank #2 (Buy).
Other top-ranked stocks in the broader technology sector include Advanced Micro Devices (AMD - Free Report) , ON Semiconductor (ON - Free Report) and ASML Holding N.V. (ASML - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Long-term earnings growth rates for ON, Advanced Micro Devices and ASML Holding are currently projected at 53.9%, 44.6% and 33.5%, respectively.